BIOSTAR PHARM-B(02563),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02563 BIOSTAR PHARM-B

Market Closed 11-22 16:08:13

28.900

-0.150

-0.52%

High29.400	Low28.200	Vol376.00K
Open29.000	D1 Closing29.050	Amplitude4.13%
Mkt Cap10.54B	Tradable Cap6.26B	Total Shares364.59M
T/O10.83M	T/O Rate0.17%	Tradable Shares216.72M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02563","market":"HK","secType":"STK","nameCN":"BIOSTAR PHARM-B","latestPrice":28.9,"timestamp":1732262893015,"preClose":29.05,"halted":0,"volume":376000,"delay":0,"floatShares":216720857,"shares":364588000,"eps":0,"marketStatus":"Market Closed","change":-0.15,"latestTime":"11-22 16:08:13","open":29,"high":29.4,"low":28.2,"amount":10825580,"amplitude":0.041308,"askPrice":28.9,"askSize":3800,"bidPrice":28.55,"bidSize":600,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1732498200000},"marketStatusCode":7,"adr":0,"listingDate":1730304000000,"exchange":"SEHK","adjPreClose":29.05,"openAndCloseTimeList":[[1732239000000,1732248000000],[1732251600000,1732262400000]],"volumeRatio":1.1636543700736033,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02563","defaultTab":"news","newsList":[{"id":"2483875579","title":"Biostar Pharma Grants Baheal Medical China Marketing Rights to Breast Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2483875579","media":"MT Newswires Live","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483875579?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:48","pubTimestamp":1731584923,"startTime":"0","endTime":"0","summary":"Beijing Biostar Pharmaceuticals  granted Qingdao Baheal Medical  unit Baheal Zhihe exclusive marketing rights in mainland China for its breast cancer drug Utidelone.Under the agreement, Baheal Zhihe will exclusively market and promote Utidelone under the brand Youtidi to all medical institutions and pharmaceutical retail enterprises on the mainland.Baheal will pay Biostar Pharma 50 million yuan in downpayment and sales milestone payments in the future, according to a Thursday disclosure with the Hong Kong Exchange.Meanwhile, Chengdu Biostar Pharmaceuticals will take over marketing responsibilities for Utidelone in Hong Kong, Macau, and Taiwan.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0250","301015","02563"],"gpt_icon":0},{"id":"2483824788","title":"BRIEF-Beijing Biostar Pharmaceuticals Says To Grant Baheal Zhihe Exclusive Marketing Rights","url":"https://stock-news.laohu8.com/highlight/detail?id=2483824788","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483824788?lang=en_us&edition=fundamental","pubTime":"2024-11-14 18:36","pubTimestamp":1731580613,"startTime":"0","endTime":"0","summary":"BRIEF-Beijing Biostar Pharmaceuticals Says To Grant Baheal Zhihe Exclusive Marketing RightsNov 14  - Beijing Biostar Pharmaceuticals Co Ltd 2563.HK:TO GRANT BAHEAL ZHIHE EXCLUSIVE RIGHT TO PROVIDE MARKETING SERVICE FOR UTIDELONE INJECTIONBEIJING BAHEAL ZHIHE MEDICAL ACHIEVEMENT TRANSFORMATION SERVICE TO PAY CO DOWN PAYMENT OF RMB50 MILLIONFurther company coverage: 2563.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nFWN3ML04X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02563"],"gpt_icon":0},{"id":"2483420828","title":"Beijing Biostar Pharmaceuticals - Beijing Baheal Zhihe Medical Achievement Transformation Service to Pay Co Down Payment of RMB50 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2483420828","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483420828?lang=en_us&edition=fundamental","pubTime":"2024-11-14 16:36","pubTimestamp":1731573403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nFWN3ML04X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02563"],"gpt_icon":0},{"id":"2483037842","title":"Beijing Biostar Pharmaceuticals Co Ltd - to Grant Baheal Zhihe Exclusive Right to Provide Marketing Service for Utidelone Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2483037842","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483037842?lang=en_us&edition=fundamental","pubTime":"2024-11-14 16:36","pubTimestamp":1731573403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nFWN3ML04X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02563"],"gpt_icon":0},{"id":"2482228767","title":"Are Investors Undervaluing CLP Holdings Limited (HKG:2) By 32%?","url":"https://stock-news.laohu8.com/highlight/detail?id=2482228767","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482228767?lang=en_us&edition=fundamental","pubTime":"2024-11-11 08:01","pubTimestamp":1731283301,"startTime":"0","endTime":"0","summary":"Key Insights Using the 2 Stage Free Cash Flow to Equity, CLP Holdings fair value estimate is HK$97.96 CLP Holdings...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/9521000-choice2-main-header/1585186610142","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9521000-choice2-main-header/1585186610142"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/utilities/hkg-2/clp-holdings-shares/news/are-investors-undervaluing-clp-holdings-limited-hkg2-by-32","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1497734951.SGD","BK4100","03145","00002","TV","IE00BG0RBZ43.SGD","LU1522347837.USD","LU1634259391.SGD","BK1577","DCF","LU1497733631.SGD","02465","BK1527","LU1634259557.SGD","LU1497733557.USD","BK1099","BK4211","IE00BHRH8C09.USD","02519","LU0831103253.SGD","LU0898667661.SGD","ISBC","FCF","02563"],"gpt_icon":0},{"id":"2479771992","title":"Beijing Biostar Pharmaceutical Surges in Hong Kong Debut After HK$196 Million IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2479771992","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479771992?lang=en_us&edition=fundamental","pubTime":"2024-10-31 16:59","pubTimestamp":1730365187,"startTime":"0","endTime":"0","summary":"Beijing Biostar Pharmaceuticals  made a stellar trading debut in Hong Kong on Thursday, Oct. 31.The biotech firm closed at HK$20.8 per share, up 30% from its IPO price of HK$16, after an over 34% gain at the opening bell.The oncology-focused biopharmaceutical company raised HK$196 million in net proceeds from its initial public offering after pricing the shares at the lower end of the indicative range.The drugmaker issued 14,588,000 shares at HK$16 apiece, the bottom of its guidance of as high as HK$22 each, according to a Thursday disclosure.The deal's public offering portion was 21.45 times oversubscribed, prompting the company to reallocate 291,800 shares from the international offering, which was not fully subscribed.A total of 1,750,600 shares were issued under the public offer, while 12,837,400 shares were issued under the international offer.IPO proceeds will be used for clinical trials, production capacity expansion, and marketing efforts.Price : $18607.93, Change: $-100, Perce","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HKD","BK4585","BK4526","BK4588","BK4023","02563"],"gpt_icon":0},{"id":"2479779833","title":"Hong Kong Stocks Extend Losses; Beijing Biostar Pharmaceuticals Soars 30% in Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2479779833","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479779833?lang=en_us&edition=fundamental","pubTime":"2024-10-31 16:45","pubTimestamp":1730364330,"startTime":"0","endTime":"0","summary":"Hong Kong stocks fell for a second day straight Thursday, taking cues from overnight losses on Wall Street as U.S. chip stocks tumbled and investors awaited corporate earnings.The Hang Seng Index fell","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HHImain","02563","HSI","513600","MCHmain","02551","02519","02833"],"gpt_icon":0},{"id":"1112012563","title":"Stock Track | Biostar Pharmaceuticals Soars 61.87% in Market Debut After Successful $344 Million IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1112012563","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112012563?lang=en_us&edition=fundamental","pubTime":"2024-10-31 16:30","pubTimestamp":1730363440,"startTime":"0","endTime":"0","summary":"Shares of Beijing Biostar Pharmaceuticals Co Ltd, a clinical-stage biopharmaceutical company, surged 61.87% on its first trading day in Hong Kong after pricing its initial public offering  at HK$16.00  per share. The significant stock price increase reflects strong investor demand for the Chinese firm's shares, which raised around $344 million in the global offering.Founded in 2020, Biostar Pharmaceuticals is focused on developing innovative therapeutics for metabolic diseases, oncology, and oth","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02563"],"gpt_icon":0},{"id":"1146934064","title":"Stock Track | Biostar Pharmaceuticals Soars 30% Following Successful $16 IPO Pricing","url":"https://stock-news.laohu8.com/highlight/detail?id=1146934064","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146934064?lang=en_us&edition=fundamental","pubTime":"2024-10-31 09:33","pubTimestamp":1730338404,"startTime":"0","endTime":"0","summary":"Shares of Beijing Biostar Pharmaceuticals Co Ltd surged 30% on Wednesday, the first trading day after the company announced the final offer price of HK$16.00  per share in its global initial public offering .The significant stock price increase reflects strong investor demand for the Chinese biopharmaceutical firm's shares. Biostar Pharmaceuticals raised around $344 million in the Hong Kong IPO, according to Reuters calculations based on the final pricing.Founded in 2020, Biostar Pharmaceuticals","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02563"],"gpt_icon":0},{"id":"2479790743","title":"Shares of Beijing Biostar Pharmaceuticals  Set to Open at HK$21.50 Each in Hong Kong Debut VS IPO Price HK$16 Apiece","url":"https://stock-news.laohu8.com/highlight/detail?id=2479790743","media":"THOMSON REUTERS","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479790743?lang=en_us&edition=fundamental","pubTime":"2024-10-31 09:22","pubTimestamp":1730337745,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241031:nL4N3M703Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02563"],"gpt_icon":0},{"id":"2479878053","title":"BRIEF-Beijing Biostar Pharmaceuticals Announces Final Offer Price Under Global Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2479878053","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479878053?lang=en_us&edition=fundamental","pubTime":"2024-10-30 23:15","pubTimestamp":1730301322,"startTime":"0","endTime":"0","summary":"Oct 30 (Reuters) - Beijing Biostar Pharmaceuticals Co Ltd   :   * FINAL OFFER PRICE OF HK$16.000 UNDER GLOBAL OFFERINGFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02563"],"gpt_icon":0},{"id":"2479789798","title":"Beijing Biostar Pharmaceuticals - Final Offer Price of HK$16.000 Under Global Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2479789798","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479789798?lang=en_us&edition=fundamental","pubTime":"2024-10-30 22:22","pubTimestamp":1730298170,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nFWN3M6158:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02563"],"gpt_icon":0},{"id":"2477788377","title":"Hong Kong Stocks Rebound on Earnings Optimism, Potential Stabilization Fund; China Resources Beverage Surges 15% in Trading Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2477788377","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477788377?lang=en_us&edition=fundamental","pubTime":"2024-10-23 16:49","pubTimestamp":1729673342,"startTime":"0","endTime":"0","summary":"Hong Kong stocks rose on Tuesday as investor sentiment got a boost amid the suggestion of a stock-stabilization fund worth 2 trillion yuan by a state-supported think tank and upbeat expectations for c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02563","02460","HSI","OP.USD.HKCC"],"gpt_icon":1},{"id":"2477731702","title":"Beijing Biostar Pharmaceuticals Looks to Raise Up to HK$321 Million from Hong Kong IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2477731702","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477731702?lang=en_us&edition=fundamental","pubTime":"2024-10-23 09:32","pubTimestamp":1729647136,"startTime":"0","endTime":"0","summary":"Beijing Biostar Pharmaceuticals  launched its initial public offering in Hong Kong, seeking to raise as much as HK$320.9 million.The pharmaceutical is offering 14,588,000 H shares at HK$16 to HK$22 apiece.Beijing Biostar secured Novotech SG, Baheal Wellness, SilkyWater Absolute Return, and Wealth Strategy as cornerstone investors, which committed to subscribe for HK$178.8 million worth of IPO shares.The issuer expects to determine its offer price on Oct. 29 and disclose the allocations on Oct. 30. It will then start trading on the Hong Kong bourse on Oct. 31, according to a Wednesday filing.Net proceeds, estimated at HK$234 million, will be used to fund core products, clinical trials, and studies for non-core products and construct a local and international marketing network. Some of the funds will also be used to enhance production capabilities, and the rest will be used for general working capital needs.CCB International, China Securities International, ICBC, SPDB International, and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","LU0359201885.HKD","LU0287142896.SGD","IE0032431581.USD","03143","LU0359201612.USD","BK4585","LU0823426480.USD","02563","LU0823426308.USD","LU1224709979.USD","BK4023","BK1560","LU1880383366.USD","BK1521","LU1023057109.AUD","01398","LU0737861699.HKD","LU0359202008.SGD","LU1880383440.USD","BK1231","BK4526","HKD","LU0173614495.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biostar-pharm.com","stockEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.8062},{"period":"ytd","weight":0.8062}],"compareEarnings":[{"period":"1week","weight":-0.0101},{"period":"1month","weight":-0.0737},{"period":"3month","weight":0.0919},{"period":"6month","weight":0.0334},{"period":"1year","weight":0.0736},{"period":"ytd","weight":0.128}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Beijing Biostar Pharmaceuticals Co Ltd is a Chinea-based company principally engaged in the research, development, production and sales of innovative drugs. The Company's products and pipeline mainly include Utidelone Injection, Utidelone Capsule, Utidelone Nanoformulation, Utidelone Antibody Drug Conjugate (ADC), BG22, BG18 and BG44. The Company's products are principally used for the treatment of relapsed or metastatic breast cancer, neoadjuvant treatment of human epidermal growth factor receptor 2 (HER2)-breast cancer neoadjuvant, advanced non-small cell lung cancer (NSCLC), solid tumors, breast cancer brain metastasis, lung cancer brain metastasis and other brain tumor indications. The Company mainly conducts its businesses in the domestic market.","exchange":"SEHK","name":"BIOSTAR PHARM-B","nameEN":"BIOSTAR PHARM-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BIOSTAR PHARM-B(02563),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BIOSTAR PHARM-B(02563) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BIOSTAR PHARM-B,02563,BIOSTAR PHARM-B股票,BIOSTAR PHARM-B股票老虎,BIOSTAR PHARM-B股票老虎国际,BIOSTAR PHARM-B行情,BIOSTAR PHARM-B股票行情,BIOSTAR PHARM-B股价,BIOSTAR PHARM-B股市,BIOSTAR PHARM-B股票价格,BIOSTAR PHARM-B股票交易,BIOSTAR PHARM-B股票购买,BIOSTAR PHARM-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BIOSTAR PHARM-B(02563),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BIOSTAR PHARM-B(02563) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}